Biocon: From Generics Manufacturing to Biopharmaceutical Innovation Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Biocon: From Generics Manufacturing to Biopharmaceutical Innovation case study

At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Biocon: From Generics Manufacturing to Biopharmaceutical Innovation case study is a Harvard Business School (HBR) case study written by Jeroen Van Den Berg, Michael J. Enright, Venkat Subramanian. The Biocon: From Generics Manufacturing to Biopharmaceutical Innovation (referred as “Biocon Biopharmaceutical” from here on) case study provides evaluation & decision scenario in field of Strategy & Execution. It also touches upon business topics such as - Value proposition, Innovation.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment

---

Case Description of Biocon: From Generics Manufacturing to Biopharmaceutical Innovation Case Study

Incorporated in 1978 as a joint venture between Biocon Biochemicals Ltd, Ireland and a company led by Ms. Kiran Mazumdar-Shaw, a young Indian entrepreneur, Biocon had long depended on revenues from the production of enzymes and generic drugs. However, competitive pressure from within the country as well as from other developing economies like China was quickly eroding price levels in these lines of business. Moreover, the 2005 adoption of WTO TRIPS in India meant that the generics-based strategy that many of India's pharma and biotech companies had followed might not be viable anymore. To continue on its current growth path, Biocon needed to consider moving from being a producer of biogenerics to becoming a global biopharmaceutical innovator. Concerned with strategy in an emerging industry, sheds light on the effects of clusters on strategy, as well as the effects of national and supranational factors on strategy. Leadership issues and low-cost strategies for diversification are also addressed.

Case Authors : Jeroen Van Den Berg, Michael J. Enright, Venkat Subramanian

Topic : Strategy & Execution

Related Areas : Innovation

---

Calculating Net Present Value (NPV) at 6% for Biocon: From Generics Manufacturing to Biopharmaceutical Innovation Case Study

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 6 %	Discounted Cash Flows
Year 0	(10010103)	-10010103	-	-
Year 1	3451935	-6558168	3451935	0.9434	3256542
Year 2	3955780	-2602388	7407715	0.89	3520630
Year 3	3947673	1345285	11355388	0.8396	3314542
Year 4	3246001	4591286	14601389	0.7921	2571137
TOTAL			14601389		12662852

The Net Present Value at 6% discount rate is 2652749

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting

What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.

---

Capital Budgeting Approaches

Methods of Capital Budgeting

There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Payback Period
2. Net Present Value
3. Internal Rate of Return
4. Profitability Index

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Biocon Biopharmaceutical shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.
2. Timing of the expected cash flows – stockholders of Biocon Biopharmaceutical have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.

---

Formula and Steps to Calculate Net Present Value (NPV) of Biocon: From Generics Manufacturing to Biopharmaceutical Innovation

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Strategy & Execution Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Biocon Biopharmaceutical often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Biocon Biopharmaceutical needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 15 %	Discounted Cash Flows
Year 0	(10010103)	-10010103	-	-
Year 1	3451935	-6558168	3451935	0.8696	3001683
Year 2	3955780	-2602388	7407715	0.7561	2991138
Year 3	3947673	1345285	11355388	0.6575	2595659
Year 4	3246001	4591286	14601389	0.5718	1855912
TOTAL					10444391

The Net NPV after 4 years is 434288

(10444391 - 10010103 )

---

Calculating Net Present Value (NPV) at 20%

If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 20 %	Discounted Cash Flows
Year 0	(10010103)	-10010103	-	-
Year 1	3451935	-6558168	3451935	0.8333	2876613
Year 2	3955780	-2602388	7407715	0.6944	2747069
Year 3	3947673	1345285	11355388	0.5787	2284533
Year 4	3246001	4591286	14601389	0.4823	1565394
TOTAL					9473609

The Net NPV after 4 years is -536494

At 20% discount rate the NPV is negative (9473609 - 10010103 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Biocon Biopharmaceutical to discount cash flow at lower discount rates such as 15%.

Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Biocon Biopharmaceutical has a NPV value higher than Zero then finance managers at Biocon Biopharmaceutical can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Biocon Biopharmaceutical, then the stock price of the Biocon Biopharmaceutical should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Biocon Biopharmaceutical should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What will be a multi year spillover effect of various taxation regulations.

What can impact the cash flow of the project.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

Understanding of risks involved in the project.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.

---

Negotiation Strategy of Biocon: From Generics Manufacturing to Biopharmaceutical Innovation

References & Further Readings

Jeroen Van Den Berg, Michael J. Enright, Venkat Subramanian (2018), "Biocon: From Generics Manufacturing to Biopharmaceutical Innovation Harvard Business Review Case Study. Published by HBR Publications.